Geetha A. Subramaniam

Rising rates of opioid use among teenagers and young adults are a public health concern. Despite short durations of opioid use compared with those of adults, youth with opioid dependence have a host of co-occurring conditions, including polysubstance abuse, psychiatric disorders, hepatitis C infection, HIV risk, and high-risk sexual and criminal behaviors. Opioid-dependent youth typically are offered outpatient/residential treatment with brief detoxification, but one study showed that heroin users fare worse following residential treatment. Although abundant research supports the use of medication-assisted treatment for opioid-dependent adults, research is only recently emerging for youth. Buprenorphine, a partial opioid agonist, was proven safe and effective in improving abstinence from opioids in two controlled clinical trials. More research is needed to determine several clinically relevant areas: appropriate duration of agonist treatment, ways to enhance medication adherence, the value of integrated treatments for co-occurring conditions, and the role of opioid antagonists in opioid-dependent youth.

This study examines the demographic and clinical correlates and time course of depressive symptoms among abstinent adolescents with substance use disorders (SUD) during residential treatment. Fifty‐six adolescents were administered the Beck Depression Inventory at Weeks 1, 3, and 5 of residential treatment for SUD. Clinically significant depression persisted in a substantial minority at the time of discharge. Shorter length of stay patients reported higher baseline scores and a significant decline by Week 3. Longer length of stay patients showed significant decline in scores only at Week 5. Females, Caucasians, and high frequency cocaine) opiates users had elevated depressive symptoms, while those with shorter duration of abstinence did not.